Dopamine agonists and analogues have an antiproliferative effect on CHO-K1 cells

R Maggio1, M Armogida, M Scarselli

  • 1Department of Neuroscience, University of Pisa, Pisa, Italy. r.maggio@drugs.med.unipi.it

Insights

Parkinson's disease treatments, like L-DOPA and dopamine agonists, show antiproliferative effects on cancer cells. Apomorphine is the most potent inhibitor, but the mechanism is not oxidative stress.

Area of Science:

  • Pharmacology
  • Oncology
  • Neuroscience

Background:

  • Epidemiological studies suggest a lower cancer incidence in Parkinson's disease patients.
  • Parkinson's disease treatments, including L-beta-3,4-dihydroxyphenylalanine (L-DOPA) and dopamine (DA) agonists, are widely used.
  • The potential influence of these therapeutic agents on cancer risk warrants investigation.

Purpose of the Study:

  • To investigate the antiproliferative effects of L-DOPA, DA agonists, and related compounds on cancer cell growth.
  • To explore the role of oxidative potential in the antiproliferative mechanism of these agents.

Main Methods:

  • Assessed the antiproliferative activity of various compounds, including apomorphine, DA, L-DOPA, and bromocriptine, on Chinese hamster ovary (CHO)-K1 cells.
  • Investigated the effect of antioxidants like glutathione (GSH) and dithiothreitol (DTT) on reversing antiproliferative effects.
  • Utilized dihydrorhodamine 123 to assess the oxidative potential of the compounds.

Main Results:

  • Apomorphine demonstrated the most potent inhibition of CHO-K1 cell growth (EC50 of 3.35 +/- 0.12 micro M).
  • DA, 6-hydroxydopamine (6-OHDA), phenylethylamine (PEA), L-DOPA, and bromocriptine showed lower antiproliferative activity.
  • GSH and DTT reversed the effects of apomorphine, DA, and 6-OHDA, but not bromocriptine, suggesting a complex mechanism not solely reliant on oxidative potential.

Conclusions:

  • Apomorphine and related compounds exhibit significant antiproliferative effects on cancer cells.
  • The antiproliferative activity is not primarily mediated by oxidative potential.
  • Further research is needed to elucidate the precise mechanism underlying the observed effects.

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Drugs Affecting Neurotransmitter Synthesis01:29

Drugs Affecting Neurotransmitter Synthesis

Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase, which converts...
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists01:28

Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists

Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists01:29

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...